4-azido-2-(trifluoromethyl)benzonitrile | 1449785-87-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-azido-2-(trifluoromethyl)benzonitrile
• 英文别名: 4-Azido-2-(trifluoromethyl)benzonitrile
• CAS: 1449785-87-8
• 化学式: C₈H₃F₃N₄
• 分子量: 212.134
• InChiKey: FFKHCSMGRPZPMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-azido-2-(trifluoromethyl)benzonitrile 在 copper(ll) sulfate pentahydrate 、 硫酸 、 硝酸 、 potassium carbonate 、 sodium ascorbate 作用下， 以 甲醇 、 水 为溶剂， 反应 30.0h， 生成 2-nitro-4-(1H-1,2,3-triazol-1-yl)-6-(trifluoromethyl)benzonitrile
  参考文献：
  名称：

  三氟甲基取代的N-芳基-聚1,2,3-三唑衍生物的合成†

  摘要：

  报道了–CF 3和–NO 2取代的N-芳基-聚三唑衍生物的合成，表征和物理性质。这些分子是通过在–CF 3取代的芳基叠氮化物和炔烃之间进行可靠的Cu催化的[3 + 2]环加成而制备的，随后是硝化序列，以及由1,2,3引起的卤素基团的碱基促进的亲核取代-三唑。该化合物通过分析和光谱学方法表征。X射线衍射技术证实了某些化合物的固态结构。合成材料在195–308°C的范围内分解。大部分–CF 3和–NO 2带有基团的芳基三唑显示出良好的密度和可接受的爆炸特性。一些含氟聚三唑的化合物显示出正的形成热。

  DOI：

  10.1039/c3ta15184k
• 作为产物：
  描述：

  4-氨基-2-三氟甲基苯甲腈 在 亚硝酸特丁酯 、 叠氮基三甲基硅烷 作用下， 以 乙腈 为溶剂， 反应 2.0h， 生成 4-azido-2-(trifluoromethyl)benzonitrile
  参考文献：
  名称：

  1,4-取代的三唑类作为非甾体类抗雄激素治疗前列腺癌的方法

  摘要：

  前列腺癌（PC）是男性死于癌症的第五大原因，而雄激素受体（AR）则是PC治疗的主要目标，即使该疾病通常会发展为非雄激素依赖性疾病。大多数可商购的非甾体抗雄激素显示出由两个通过线性或环状间隔基连接的芳环组成的普通支架。通过利用一种容易的，一锅法单击的化学反应，我们在这里报道了具有AR拮抗活性的新型1,4-取代的三唑的小文库的制备。生物学和理论评估表明，将三唑核心引入非甾体抗雄激素支架中可以开发出具有改善的整体AR拮抗剂活性的小分子。实际上，化合物14d展示了对三种不同前列腺癌细胞系的有希望的体外抗肿瘤活性，并且能够在体内异种移植模型中诱导CW22Rv1抑制60％的肿瘤生长。这些结果代表了开发新的和改进的AR拮抗剂的一步。

  DOI：

  10.1021/acs.jmedchem.7b00105

文献信息

• 5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: Solution and X-ray crystallographic studies
  作者：Janis Leitans、Agnese Sprudza、Muhammet Tanc、Igor Vozny、Raivis Zalubovskis、Kaspars Tars、Claudiu T. Supuran

  DOI：10.1016/j.bmc.2013.06.041

  日期：2013.9

  We report here a series of 2-thiophene-sulfonamides incorporating 1-substituted aryl-1,2,3-triazolyl moieties, prepared by click chemistry from 5-ethynylthiophene-2-sulfonamide and substituted aryl azides. The new sulfonamides were investigated as inhibitors of the zinc metalloenzyme CA (EC 4.2.1.1), and more specifically against the human (h) cytosolic isoforms hCA I and II and the transmembrane, tumor-associated ones hCA IX and XII: The new compounds were medium-weak hCA I inhibitors (K(I)s in the range of 224-7544 nM), but were compactly, highly effective, low nanomolar hCA II inhibitors (K(I)s of 2.2-7.7 nM). The tumor-associated hCA IX was inhibited with K(I)s ranging between 5.4 and 811 nM, whereas hCA XII with inhibition constants in the range of 3.4-239 nM. The X-ray crystal structure of the adducts of two such compounds bound to hCA II (one incorporating 1-naphthyl, the other one 3-cyanophenyl moieties) evidenced the reasons of the high affinity for hCA II. Highly favorable, predominantly hydrophobic interactions between the sulfonamide scaffold and the hCA II active site were responsible for the binding, in addition to the coordination of the sulfamoyl moiety to the zinc ion. The tails of the two inhibitors adopted very diverse orientations when bound to the active site, with the naphthyltriazolyl moiety orientated towards the hydrophobic half of the active site, and the 3-cyanophenyl one pointing towards the hydrophilic half. These data may be used for the structure-based drug design of even more effective hCA II inhibitors, with potential use as antiglaucoma agents or as diuretics. (C) 2013 Elsevier Ltd. All rights reserved.
• Preliminary investigations into triazole derived androgen receptor antagonists
  作者：Jarrad M. Altimari、Birunthi Niranjan、Gail P. Risbridger、Stephanie S. Schweiker、Anna E. Lohning、Luke C. Henderson

  DOI：10.1016/j.bmc.2014.03.018

  日期：2014.5

  A range of 1,4-substituted-1,2,3-N-phenyltriazoles were synthesized and evaluated as non-steroidal androgen receptor (AR) antagonists. The motivation for this study was to replace the N-phenyl amide portion of small molecule antiandrogens with a 1,2,3-triazole and determine effects, if any, on biological activity. The synthetic methodology presented herein is robust, high yielding and extremely rapid. Using this methodology a series of 17 N-aryl triazoles were synthesized from commercially available starting materials in less than 3 h. After preliminary biological screening at 20 and 40 mu M, the most promising three compounds were found to display IC50 values of 40-50 mu M against androgen dependent (LNCaP) cells and serve as a starting point for further structure-activity investigations. All compounds in this work were the focus of an in silico study to dock the compounds into the human androgen receptor ligand binding domain (hARLBD) and compare their predicted binding affinity with known antiandrogens. A comparison of receptor-ligand interactions for the wild type and T877A mutant AR revealed two novel polar interactions. One with Q738 of the wild type site and the second with the mutated A877 residue. (C) 2014 Elsevier Ltd. All rights reserved.
• Novel 1,4-Substituted-1,2,3-Triazoles as Antitubercular Agents
  作者：Jarrad M. Altimari、Samantha C. Hockey、Helena I. Boshoff、Andaleeb Sajid、Luke C. Henderson

  DOI：10.1002/cmdc.201500051

  日期：2015.5

  AbstractTuberculosis (TB) remains a pressing unmet medical need, particularly with the emergence of multidrug‐resistant and extensively drug‐resistant tuberculosis. Here, a series of 1,4‐substituted‐1,2,3‐triazoles have been synthesized and evaluated as potential antitubercular agents. These compounds were assembled via click chemistry in high crude purity and in moderate to high yield. Of the compounds tested, 12 compounds showed promising antitubercular activity with six possessing minimum inhibitory concentration (MIC) values <10 μg mL−1, and total selectivity for Mycobacterium tuberculosis (Mtb) growth inhibition. A second set of 21 compounds bearing variations on ring C were synthesized and evaluated. This second library gave an additional six compounds displaying MIC values ≤10 μg mL−1 and total selectivity for Mtb growth inhibition. These compounds serve as an excellent starting point for further development of antitubercular therapies.
• ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS
  申请人：Stratos Genomics Inc.

  公开号：EP3994262A1

  公开（公告）日：2022-05-11
• [EN] ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS<br/>[FR] AMÉLIORATION DE LA POLYMÉRISATION D'ACIDES NUCLÉIQUES PAR DES COMPOSÉS AROMATIQUES
  申请人：STRATOS GENOMICS INC

  公开号：WO2020263703A1

  公开（公告）日：2020-12-30

  The invention relates to compounds, methods and compositions for improving on nucleic acid polymerization, including DNA replication by in vitro primer extension to generate, for example, polymers for nanopore-based single molecule sequencing of a DNA template. A nucleic acid polymerase reaction composition is provided with polymerization enhancement moieties, which allows enhanced DNA polymerase activity with nucleotide analogs, resulting in improved length of primer extension products for sequencing applications.